MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats

Chao, Guanqun; Wang, Yingying; Zhang, Shuo; Yang, Wenzhuo; Ni, Zheying; Zheng, Xiu

doi:10.18632/oncotarget.20687

Cited by 17 publications

(11 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a mouse model of intestinal ischaemia reperfusion injury showed increased miR-874 levels and decreased AQP3 protein levels, an effect that was similarly observed in Caco-2 cells under hypoxia, where miR-874 induced paracellular permeability by inhibiting AQP3 expression contributing to the impairment of intestinal barrier integrity ( Su et al, 2016 ). This same effect was reported for miR-29a in diarrhea-predominant irritable bowel syndrome rat models ( Chao et al, 2017 ). Overexpression of long non-coding RNA (lncRNA) H19, a miR-874 sponge, could revert the miR-874 induced effects and reduce paracellular permeability, suggesting its potential role in reestablishing the intestinal barrier function ( Su et al, 2016 ).…”

Section: Aquaglyceroporin Modulators With Pharmacological Actionsupporting

confidence: 84%

Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases

Pimpão

Wragg

Casini

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Aquaglyceroporins, a sub-class of aquaporins that facilitate the diffusion of water, glycerol and other small uncharged solutes across cell membranes, have been recognized for their important role in human physiology and their involvement in multiple disorders, mostly related to disturbed energy homeostasis. Aquaglyceroporins dysfunction in a variety of pathological conditions highlighted their targeting as novel therapeutic strategies, boosting the search for potent and selective modulators with pharmacological properties. The identification of selective inhibitors with potential clinical applications has been challenging, relying on accurate assays to measure membrane glycerol permeability and validate effective functional blockers. Additionally, biologicals such as hormones and natural compounds have been revealed as alternative strategies to modulate aquaglyceroporins via their gene and protein expression. This review summarizes the current knowledge of aquaglyceroporins’ involvement in several pathologies and the experimental approaches used to evaluate glycerol permeability and aquaglyceroporin modulation. In addition, we provide an update on aquaglyceroporins modulators reported to impact disease, unveiling aquaglyceroporin pharmacological targeting as a promising approach for innovative therapeutics.

show abstract

Section: Aquaglyceroporin Modulators With Pharmacological Actionsupporting

confidence: 84%

Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases

Pimpão

Wragg

Casini

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Furthermore, miR-29a levels are significantly lower in CKD patients as compared with controls [ 29 ]. Of note, animal [ 30 ] and human studies [ 31 ] have documented a direct relationship between miR-29a levels and the extent of intestinal permeability. Taken together, and besides the effects of impaired renal excretion of sucralose per se, these findings could explain, at least in part, the decreased colon permeability of sucralose observed in the present cohort of CKD patients.…”

Section: Discussionmentioning

confidence: 99%

An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients

Cosola

Rocchetti

Bari

et al. 2021

Toxins

View full text Add to dashboard Cite

Proteolytic dysbiosis of the gut microbiota has been recognized as both a typical feature of chronic kidney disease (CKD) and a risk factor for its progression. Blood accumulation of gut-derived uremic toxins (UTs) like indoxyl sulfate (IS) and p-cresyl sulfate (PCS), intestinal permeability and constipation are typical features accompanying CKD progression and triggering chronic inflammation. In order to verify the efficacy of the innovative synbiotic formulation NATUREN G® in modulating the levels of circulating UTs, intestinal permeability and gastrointestinal symptoms, we set up a randomized, single-blind, placebo-controlled, pilot trial in stage IIIb-IV CKD patients and in healthy controls. Two-month administration of the synbiotic resulted in a decrease of free IS, as compared with the placebo-treated arm, only in the CKD group. The other UTs did not significantly change, although different trends in time (increase in the placebo arm and decrease in the synbiotic arm) were observed. Moreover, after supplementation, reduction of small intestinal permeability and amelioration of abdominal pain and constipation syndromes were observed only in the CKD group. The obtained results suggest the specificity of action of NATUREN G® in CKD and justify further validation in a wider study population.

show abstract

“…miR-29a and miR-29b prevented inflammation in mice after DSS-induced colitis when delivered with supercarbonate apatite nanoparticle (417). Increased levels of miR-29a have also been found in blood, small bowel and colon in IBS and colon in IBD patients (113,418,419), but, as a matter of fact, its role is sometimes contradictory (420). miR-29a overexpression increased epithelial permeability by targeting glutamine synthetase gene (GLUL), alteration that has been previously associated with increased membrane permeability (113).…”

Section: Epigenetic and Exosome-mediated Regulation Of Intestinal Barrier Functionmentioning

confidence: 99%

Present and Future Therapeutic Approaches to Barrier Dysfunction

et al. 2021

View full text Add to dashboard Cite

There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.

show abstract

MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats

Cited by 17 publications

References 34 publications

Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases

Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases

An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients

Present and Future Therapeutic Approaches to Barrier Dysfunction

Contact Info

Product

Resources

About